Techniques for encapsulating bioactive agents into liposomes

doi:10.1016/0009-3084(86)90077-0

Chemistry and Physics of Lipids

Volume 40, Issues 2–4, June–July 1986, Pages 333-345

https://doi.org/10.1016/0009-3084(86)90077-0 Get rights and content

Abstract

As a prerequisite for the use of liposomes for delivery of biologically active agents, techniques are required for the efficient and rapid entrapment of such agents in liposomes. Here we review the variety of procedures available for trapping hydrophilic and hydrophobic compounds. Considerations which are addressed include factors influencing the choice of a particular liposomal system and techniques for the passive entrapment of drugs in multilamellar vesicles and unilamellar vesicles. Attention is also paid to active trapping procedures relying on the presence of (negatively) charged lipid or transmembrane ion gradients. Such gradients are particularly useful for concentrating lipophilic cationic drugs inside liposomes, allowing trapping efficiencies approaching 100%.

References (101)

S.B. Kaye
Cancer Treat. Rev.
(1981)
G. Gregoriadis
FEBS Lett.
(1973)
J.N. Weinstein et al.
Pharmacol. Ther.
(1984)
W.C. Koff et al.
Antiviral Res.
(1985)
C.R. Alving et al.
Life Sci.
(1980)
C. Kirby et al.
FEBS Lett.
(1980)
G. Scherphof et al.
Biochim. Biophys. Acta
(1978)
R.M. Abra et al.
J. Pharm. Sci.
(1984)
J. Senior et al.
Biochim. Biophys. Acta
(1985)
R.M. Abra et al.
Biochim. Biophys. Acta
(1981)

M.E. Bosworth et al.

J. Pharm. Sci.

(1982)

J. Senior et al.

FEBS Lett.

(1982)

G. Gregoriadis et al.

FEBS Lett.

(1980)

M. Arrowsmith et al.

Int. J. Pharmaceut.

(1984)

A.L. Weiner et al.

J. Pharmaceut. Sci.

(1985)

D. Papahadjopoulos et al.

Biochim. Biophys. Acta

(1967)

Y. Barenholzt et al.

FEBS Lett.

(1979)

Y. Kagawa et al.

J. Biol. Chem.

(1971)

D.W. Deamer et al.

Biochim. Biophys. Acta

(1976)

F. Olson et al.

Eur. J. Cancer Clin. Oncol.

(1982)

M.J. Hope et al.

Biochim. Biophys. Acta

(1985)

F. Olson et al.

Biochim. Biophys. Acta

(1979)

L.D. Mayer et al.

Biochim. Biophys. Acta

(1985)

U. Pick

Arch. Biochem. Biophys.

(1981)

M. Kasahara et al.

J. Biol. Chem.

(1977)

L.D. Mayer et al.

Biochim. Biophys. Acta

(1985)

L.D. Mayer et al.

Biochim. Biophys. Acta

(1986)

M.B. Bally et al.

Biochim. Biophys. Acta

(1985)

L.D. Mayer et al.

J. Biol. Chem.

(1985)

J.W. Nichols et al.

Biochim. Biophys. Acta

(1976)

L.M. Crowe et al.

Arch. Biochem. Biophys.

(1985)

P.R. Cullis et al.

G. Poste

Biol. Cell

(1983)

G. Gregoriadis et al.

Eur. J. Biochem.

(1972)

G. Gregoriadis et al.

Biochem. J.

(1972)

J.N. Weinstein

Cancer Treat. Rep.

(1984)

M.J. Poznansky et al.

Pharmacol. Rev.

(1984)

G. Lopez-Berestein et al.

J. Infect. Dis.

(1983)

G. Lopez-Berestein et al.

J. Infect. Dis.

(1984)

J. Ahrens et al.

J. Med. Vet. Mycol.

(1984)

G. Lopez-Berestein et al.

J. Infect. Dis.

(1985)

M.W. Fountain et al.

J. Infect. Dis.

(1981)

M.A. Vladimirsky and G.A. Ladigina, 36 (1982)...

J.R. Graybill et al.

J. Infect. Dis.

(1982)

J.V. Desiderio et al.

J. Reticulo. Soc.

(1983)

A.J.M. Bakker-Wonderbeg et al.

J. Infect. Dis.

(1985)

M.W. Fountain et al.

J. Infect. Dis.

(1985)

T. Tadakuma et al.

Antimicrob. Agents Chemother.

(1985)

C.R. Alving et al.

G.M. Barratt et al.

Cited by (151)

Supramolecular complex of tetracationic porphyrin with acyclic cucurbituril-like container induces quantitative singlet oxygen generation. Phototoxicity studies in vitro in MCF-7 human breast cancer cells
2024, Journal of Photochemistry and Photobiology A: Chemistry
Singlet oxygen generation by porphyrin-based photosensitizers is one of the main strategies used in the photodynamic therapy of cancerous lesions. In this work, we report that the complexation of tetracationic 5,10,15,20-tetrakis(N-methylpiridinium-4-yl)porphyrin (TMPyP) with an acyclic cucurbituril-like container denominated M2C4 achieves quantitative generation of singlet oxygen. The complexation was studied by isothermal titration calorimetry, revealing a highly favored binding event controlled by enthalpic contributions, a stoichiometry of 1:1 and a high binding constant (K = (1.7 ± 0.2) × 10⁷ M⁻¹). Photophysical studies of the complex showed bathochromic shifts in the absorption bands, increased fluorescence emission quantum yield and lengthened fluorescence lifetime. Nonetheless, fluorescence emission was minor, being intersystem crossing with the consequent generation of singlet oxygen the main deactivation pathway for the excited state. All these properties were compared with the previously reported TMPyP and cucurbit[7]uril (CB[7]) complex, which showed a superiority of the acyclic complex in terms of quantum efficiencies. Phototoxicity studies in a breast cancer cell line (MCF-7) cultured in vitro, showed that the TMPyP@M2C4 complex is unable to enter the cells even after a 24 h incubation period. However, this issue could be circumvented by encapsulating the complex into liposomes which delivered the complex to the cells efficiently. Overall, this strategy showed good potential for a highly efficient photodynamic treatment using the TMPyP@M2C4 complex in liposomal formulations.
Increased delivery and cytotoxicity of doxorubicin in HeLa cells using the synthetic cationic peptide pEM-2 functionalized liposomes
2023, Colloids and Surfaces B: Biointerfaces
Due to the inability of nano-carriers to passively cross the cell membrane, cell penetration enhancers are used to accelerate cytoplasmic delivery of antineoplastic drugs. In this regard, snake venom phospholipase A2 peptides are known for their ability to destabilize natural and artificial membranes. In this context, functionalized liposomes with peptide pEM-2 should favor the incorporation of doxorubicin and increase its cytotoxicity in HeLa cells compared to free doxorubicin, and doxorubicin encapsulated in non-functionalized liposomes.
Several characteristics were monitored, including doxorubicin loading capacity of the liposomes, as well as the release and uptake before and after functionalization. Cell viability and half-maximal inhibition concentrations were determined in HeLa cells.
In vitro studies showed that functionalization of doxorubicin-loaded PC-NG liposomes with pEM-2 not only improved the amount of doxorubicin delivered compared to free doxorubicin or other doxorubicin-containing formulations, but also showed enhanced cytotoxicity against HeLa cells. The PC-NG liposomes loaded with doxorubicin improved treatment efficacy by reducing the IC₅₀ value and incubation time. This increase in cell toxicity was directly related to the concentration of pEM-2 peptide bound to the liposomes. We conclude that the cytotoxicity observed in HeLa cells due to the action of doxorubicin was strongly favored when encapsulated in synthetic liposomes and functionalized with the pEM-2 peptide.
Novel bioengineering strategies for drug delivery systems
2023, Applied Materials Today
Cellular membrane-derived vesicles (CMVs) have recently attracted attention as a drug delivery system (DDS) because CMVs offer unique advantages, including nanosized particles, superior transcellular cross-communication, excellent biocompatibility, and active targeting ability. However, some challenges remain in the design and production of CMVs, such as their low yield, chemical and mechanical instability, and difficulties in functionalizing membrane surfaces. In this paper, we introduce three strategies to overcome the limitation of CMVs. First, hybrid vesicles combined CMVs from cellular membranes with synthetic liposomes (SLs) offer new engineering solutions to tackle such issues. The membrane fusion of SLs and CMVs can increase their production yield and stability while allowing for the presentation of surface proteins from donor cells. Additional compounds, such as targeted ligands and imaging agents, can be easily integrated into CMVs by using functionalized SLs. Second, core/shell nanostructures composed of synthetic nanoparticles as cores and cell membrane structures as shells can offer unique advantages for improving the stability and preservation of the inherent capabilities of the various nanoparticles in these core/shell nanostructures. Lastly, CMV/scaffold complexes are also a pronounced approach for DDSs because the scaffold structures help CMVs or loaded therapeutic agents to sustained release. The sustainable released system extends the bioavailability of CMVs or loaded therapeutic agents for a long time in vivo. Altogether, we suggest a combination strategy of hybrid vesicle-coated nanoparticles or hybrid vesicle/scaffold complex could be a promising drug delivery system.
Skin drug delivery using lipid vesicles: A starting guideline for their development
2023, Journal of Controlled Release
Lipid vesicles can provide a cost-effective enhancement of skin drug absorption when vesicle production process is optimised. It is an important challenge to design the ideal vesicle, since their properties and features are related, as changes in one affect the others. Here, we review the main components, preparation and characterization methods commonly used, and the key properties that lead to highly efficient vesicles for transdermal drug delivery purposes. We stand by size, deformability degree and drug loading, as the most important vesicle features that determine the further transdermal drug absorption. The interest in this technology is increasing, as demonstrated by the exponential growth of publications on the topic. Although long-term preservation and scalability issues have limited the commercialization of lipid vesicle products, freeze-drying and modern escalation methods overcome these difficulties, thus predicting a higher use of these technologies in the market and clinical practice.
Flavonoid-based nanomedicines to target tumor microenvironment
2022, OpenNano
Cancer cells arise and grow in tumor microenvironment which consists of stromal cells and extracellular matrix. The dynamic interaction between cancer cells and different components of the tumor microenvironment is a critical step in cancer development and progression. Several therapeutic strategies were explored as promising approaches to target tumor microenvironment.
Flavonoids have gained increasing importance in cancer therapy due to their high bioavailability, low toxicity, and affordability. Many flavonoids showed potent activities as potential cytotoxic agents and multiple nano- formulations were tested to enhance the therapeutic effect of flavonoids.
In this review, a comprehensive analysis of flavonoid-based nanomedicine was provided with special emphasis on tumor microenvironment components as therapeutic targets. Studies discussed in this review provide a solid ground for researchers and physicians to consider flavonoid based nano- formulations as possible adjuvant therapies with conventional anticancer agents.
Stability and release of bioactives from liposomes
2022, Liposomal Encapsulation in Food Science and Technology
The health benefits of bioactive compounds have been proved beyond doubt, but their instabilities and poor bioavailabilities most often limit their full potential. Encapsulating them in vesicular carrier systems, such as liposomes or emulsions, protects the sensitive compounds against damaging factors and offers an opportunity to achieve controlled release, which in turn aims to enhance their bioavailabilities and efficacies. Liposomes and emulsions are regularly used to tackle the stability issues of bioactives, however, they themselves are susceptible to various chemical, physical, and biological instabilities. Different factors related to lipids, bioactives, and liposome size and lamellarity are known to affect both the stabilities and release behavior of liposomes. Liposomes show biphasic or triphasic release patterns with an initial burst release which is brought under control to achieve better release properties. Optimizing release-affecting factors, utilization of the bioactive–cyclodextrin complex, polymeric coating of liposomes, or encapsulation of liposomes into another polymeric matrix are reported to control the liposomal release behavior. Moreover, liposomes are designed to hold (slow or no release) their content until stimulated/triggered by some release-triggering mechanism like pH, temperature, ultrasound, etc. In comparison, double/multiple emulsion and polyelectrolyte coated multilayer emulsions can also offer controlled release of their payload. Liposomes, being made of natural ingredients, are an attractive choice as carriers for bioactives, although some challenges remain. The first is the destruction of liposomes by bile and lipases in the gastrointestinal tract, the most plausible route of administration for bioactives. In addition, they do not permeate through the gastrointestinal epithelial layers. A large amount (often 20%–30%) of cholesterol, a common ingredient required for liposome rigidity, also remains a concern for hypercholesterolemic people. However, our intense interest in bioactive substances can be expected to overcome these challenges in the near future.

View all citing articles on Scopus

View full text

Techniques for encapsulating bioactive agents into liposomes

Abstract

Cancer Treat. Rev.

FEBS Lett.

Pharmacol. Ther.

Antiviral Res.

Life Sci.

FEBS Lett.

Biochim. Biophys. Acta

J. Pharm. Sci.

Biochim. Biophys. Acta

Biochim. Biophys. Acta

J. Pharm. Sci.

FEBS Lett.

FEBS Lett.

Int. J. Pharmaceut.

J. Pharmaceut. Sci.

Biochim. Biophys. Acta

FEBS Lett.

J. Biol. Chem.

Biochim. Biophys. Acta

Eur. J. Cancer Clin. Oncol.

Biochim. Biophys. Acta

Biochim. Biophys. Acta

Biochim. Biophys. Acta

Arch. Biochem. Biophys.

J. Biol. Chem.

Biochim. Biophys. Acta

Biochim. Biophys. Acta

Biochim. Biophys. Acta

J. Biol. Chem.

Biochim. Biophys. Acta

Arch. Biochem. Biophys.

Biol. Cell

Eur. J. Biochem.

Biochem. J.

Cancer Treat. Rep.

Pharmacol. Rev.

J. Infect. Dis.

J. Infect. Dis.

J. Med. Vet. Mycol.

J. Infect. Dis.

J. Infect. Dis.

J. Infect. Dis.

J. Reticulo. Soc.

J. Infect. Dis.

J. Infect. Dis.

Antimicrob. Agents Chemother.